Skip to main content

Quotient celebrates Alnwick opening

Quotient Sciences held an official ribbon-cutting event to celebrate the opening of its new, £6 million drug substance manufacturing facility in Alnwick, UK, on 9 December. Among those present were Sharon Todd, CEO of the Society of Chemical Industry, and Quotient’s SVP and head of candidate development, Paul Ryan.

Quotient integrates drug substance into platform

Quotient Sciences, a UK-based firm that describes itself as a “drug development and manufacturing accelerator”, has integrated drug substance into its flagship Translational Pharmaceutics platform, uniting it with drug product and clinical testing activities within one organisation under a single project manager. This follows a year after the acquisition of the former Arcinova site at Alnwick.

Quotient to expand Alnwick

Quotient Sciences is to invest £6.3 million to expand drug substance manufacturing at the site in Alnwick, UK, which it acquired along with Arcinova in February. This will also create 80 new jobs over the next three years and boost its capacity to develop complex medicines tenfold.

Rebrands for AMRI and Arcinova

Two pharmaceutical CDMOs, AMRI in the US and UK-based Arcinova, have almost simultaneously announced full corporate rebranding exercises. The former has become Curia, which is derived from a Latin word for ‘purposeful assembly’, as of 12 July, while the latter is taking the name Quotient Sciences – Alnwick.

New owner for Arcinova

UK-based CDMO Arcinova has been acquired by Quotient Sciences, a ‘drug development and manufacturing accelerator’ that is itself owned by private equity firm Permira. BGF, which had part-owned Arcinova since 2018, will withdraw from its minority stake. Terms were not disclosed.

Subscribe to Alnwick